SynergyFinder™ helps to ensure that new therapies are combined in the best way possible. Many therapies, particular in oncology, are applied as combination therapies. To identify the right combination of your lead compound with standards of care or new drugs, NTRC has developed SynergyFinder™.
- Synergy testing in in vitro cellular assays
- Evaluates if combinations of two compounds have a greater than additive effect
- Allows rapid identification of the best out of many possible combinations
- Rapid workflow based on Oncolines™ cancer cell line panel
- List of drugs and drug candidates pre-profiled in Oncolines™ for rapid experimental progress
- Quantitative synergy scoring with Chou-Talalay method
- Parallel testing in the diversity of genetic backgrounds of the Oncolines™ panel.
- Drug candidate of client is tested as a single agent in the Oncolines™ panel
- Cell lines with appropriate genetic background and targetting are selected 
- Combination drugs are chosen from a pre-profiled compound list
- In case all compounds are highly active, they are combined in a fixed IC50 ratio experiment
- In case one of the compounds to be tested in combination is poorly active as single agent, a fixed dose combination experiment is used.
- IC50s and efficacies are determined by measuring cell proliferation
- Synergy parameters are scored: Curve Shift, Combination Index via the Chou-Talalay method (CI) and isobolograms
For more information and request for a quotation, please send an e-mail to email@example.com
Synergy testing requires detailed knowledge of the expected response of single agents, to be able to test the appropriate concentration ranges in a combination experiment. To expedite synergy testing, NTRC has predetermined IC50s, curve shapes and efficacy parameters of many relevant drugs and drug candidates in the OncolinesTM panel. Pre-profiled compound sets include
- recently approved small molecule oncology drugs
- targeted agents
- cytostatic agents
- epigenetic modulators
- selective tool compounds for investigational pathways
For a complete list of pre-profiled compounds, please send an e-mail to firstname.lastname@example.org
Distinguishing synergy from additivity
The goal of a SynergyFinderTM experiment is to identify cases where the joint effect of a compound combination is improved compared to the additive effects of the individual compounds.
At NTRC we have developed two experimental set-ups to measure synergy, the fixed IC50 ratio experiment and the fixed dose combination experiment.
Fixed IC50 ratio experiment
This is the most robust experiment if the single agents show well-behaved dose-response curves. Based on predetermined IC50s of the single agents, mixtures are generated with theoretical equipotency compared to the single agents. Subsequently, dose response curves of these mixtures are measured in duplicate in an OncolinesTM cellular assay. A left-ward curve shift compared to the single agent curves indicates synergy .
Example of curve shift due to synergistic interaction between a PI3-kinase and a MEK inhibitor.
As a secondary analysis, we use the experimental data to generate Chou-Talalay Combination Indices  providing an independent, quantitative assessment of synergy. The CI is dependent on the fraction effect considered (e.g. 0.75, 75% growth inhibition). Generally a CI < 1 indicates synergy for a compound pair, a CI < 0.3 indicates strong synergy .
Combination index analysis (CI) for the combination of a PI3-kinase and MEK inhibitor. Circles represent experimentally determined CI values (Chou-Talalay method).
Fixed dose combination experiment
In some cases it can be advantageous to combine fixed and variable compound doses in a synergy experiment e.g. if single agents show little activity.
In this experiment NTRC combines a fixed concentration of the first compound with seven concentrations of the second compound. The single agent activities have first been assessed in duplicate in an Oncolines™ cellular assay.
Customised studies and large combinatorial screens
The service SynergyFinder™ is highly suitable for small-scale, customised studies as well as large combinatorial screens. Customised studies can be performed for a selection of Oncolines™ cell lines and selected combinations of your compound with anti-cancer agents. Usually these studies are based on hypotheses regarding genetic background and targetting of compounds [1, 5]. Large combinatorial screens, referred to as SynergyScreen™, are generally performed for combinations of your compound with the full library of 150 pre-profiled anti-cancer agents, with the purpose to look broadly for opportunities that may go beyond rationalisation. For more information and request for a quotation, please send an e-mail to email@example.com
 Uitdehaag et al (2015) PLoS ONE 10(5): e0125021
 Zhao et al. (2004) Clin. Cancer Res. 10, 7994-8004
 Chou et al. (2010) Cancer Res. 70, 440-446
 Haagensen et al. (2012) Br. J. Cancer 106, 1386-1394
 Canté-Barrett al. (2016) Leukemia, advance online publication